Trial · NCT05974683
Treatment Strategies in IgG4-RD Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period
NCT05974683, Not applicable, Unknown, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment Strategies in IgG4-RD Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period. Trials, record NCT05974683. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05974683
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment Strategies in IgG4-RD Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period
- NCT number
- NCT05974683
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 108 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Autoimmune Diseases
- Interventions
- placebo, mycophenolate mofetil
- First posted
- 2023-08-03
- Last updated
- 2023-08-03
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The difference of relapse rate of IgG4-RD between two groups in week 52. | 52 weeks | The primary endpoint is the difference of relapse rate between two groups at 52 weeks. The definition of relapse: elevation of IgG4-RD Responder Index ≥ 2 points; new organ involvement or recurrence, with or without elevation of serum IgG4 levels. |
| Secondary | The difference of relapse rate of IgG4-RD between two groups in the week 12. | 12 weeks | |
| Secondary | The difference of relapse rate of IgG4-RD between two groups in the week 24 | 24 weeks | |
| Secondary | The difference of relapse rate of IgG4-RD between two groups in the week 36. | 36 weeks | |
| Secondary | The time and duration of relapse | 52 weeks | |
| Secondary | The changes of IgG4-RD Responder Index at week 52 | 52 weeks | |
| Secondary | The changes of serum IgG level at week 52 | 52 weeks | |
| Secondary | The changes of serum IgG4 level at week 52 | 52 weeks | |
| Secondary | The changes of erythrocyte sedimentation rate at week 52 | 52 weeks | |
| Secondary | The changes of serum C-reactive protein level at week 52 | 52 weeks |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05974683
GET https://conductscience.org/api/trials/v1/NCT05974683/registered